Investigating Endogenous Hypercortisolism Prevalence in a U.S. Population With Resistant Hypertension
Year: 2026
Type: article
Study design: Study Protocol
Abstract: BACKGROUND: Hypertension is a leading modifiable risk factor for cardiovascular disease and premature death among adults. Up to 18% of individuals with hypertension have resistant hypertension (rHTN), which substantially increases the risk of adverse clinical outcomes. Endogenous hypercortisolism can result in rHTN through multiple mechanisms. OBJECTIVES: MOMENTUM (NCT06829537) is the first large, observational, multicenter study examining the prevalence of endogenous hypercortisolism among adults with rHTN in the United States. METHODS: Target enrollment is approximately 1,000 participants. To be eligible, adults aged ≥18 years must have rHTN, defined using the American Heart Association criteria (systolic blood pressure ≥130 mm Hg despite ≥3 antihypertensive medications of different classes at maximally tolerated doses, including a diuretic, or ≥4 medications from different classes regardless of systolic blood pressure). Endogenous hypercortisolism is defined as cortisol level >1.8 μg/dL on the 1-mg overnight dexamethasone suppression test with adequate dexamethasone (≥140 ng/dL). The primary endpoint is endogenous hypercortisolism prevalence. CONCLUSIONS: MOMENTUM will provide new insight into endogenous hypercortisolism in patients with resistant hypertension.
Source: JACC Advances
Authors: Jorge Plutzky, Pam R. Taub, Deepak L. Bhatt, Omar Al Dhaybi, Vanita R. Aroda, Jan N. Basile, Michael J. Bloch, Matthew Budoff, Robert S. Busch, John B. Buse, Dianne Cheung, Elena A. Christofides, Ralph A. DeFronzo, Rodolfo J. Galindo, Yehuda Handelsman, Luke Laffin, John C. Parker, Florian Rader, Julio Rosenstock, Lance A. Sloan, Iulia Cristina Tudor, Daniel Einhorn
Institutions: Brigham and Women's Hospital, University of California San Diego, Icahn School of Medicine at Mount Sinai, Medical University of South Carolina, University of Nevada, Reno, University of California, Los Angeles, The Lundquist Institute, Harbor–UCLA Medical Center, Albany Medical College, University of North Carolina at Chapel Hill, The University of Texas at San Antonio Health Science Center, University of Miami, Cleveland Clinic, Cedars-Sinai Medical Center, Corcept Therapeutics (United States)
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,936
OpenAlex ID: W7128993905